U.S. markets closed
  • S&P Futures

    4,121.50
    -3.00 (-0.07%)
     
  • Dow Futures

    32,725.00
    -12.00 (-0.04%)
     
  • Nasdaq Futures

    13,021.25
    -10.25 (-0.08%)
     
  • Russell 2000 Futures

    1,913.00
    -1.60 (-0.08%)
     
  • Crude Oil

    90.25
    -0.25 (-0.28%)
     
  • Gold

    1,809.30
    -3.00 (-0.17%)
     
  • Silver

    20.49
    +0.01 (+0.04%)
     
  • EUR/USD

    1.0212
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2072
    -0.0004 (-0.03%)
     
  • USD/JPY

    135.1760
    +0.0600 (+0.04%)
     
  • BTC-USD

    22,827.34
    -985.61 (-4.14%)
     
  • CMC Crypto 200

    530.47
    -26.88 (-4.82%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,817.04
    -182.92 (-0.65%)
     

Are Institutions Heavily Invested In Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. We also tend to see lower insider ownership in companies that were previously publicly owned.

Xeris Biopharma Holdings is a smaller company with a market capitalization of US$285m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Xeris Biopharma Holdings.

See our latest analysis for Xeris Biopharma Holdings

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Xeris Biopharma Holdings?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Xeris Biopharma Holdings. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Xeris Biopharma Holdings' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Our data indicates that hedge funds own 13% of Xeris Biopharma Holdings. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. The company's largest shareholder is Armistice Capital LLC, with ownership of 7.6%. Meanwhile, the second and third largest shareholders, hold 5.8% and 4.5%, of the shares outstanding, respectively. In addition, we found that Paul Edick, the CEO has 1.1% of the shares allocated to their name.

Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Xeris Biopharma Holdings

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Shareholders would probably be interested to learn that insiders own shares in Xeris Biopharma Holdings, Inc.. In their own names, insiders own US$8.6m worth of stock in the US$285m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, mostly comprising of individual investors, collectively holds 57% of Xeris Biopharma Holdings shares. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Xeris Biopharma Holdings , and understanding them should be part of your investment process.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.